Plain-English translation of NCT06918912 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called Loncastuximab Tesirine in people with aggressive B-cell lymphomas (DLBCL or HGBCL) whose cancer has come back or stopped responding to CAR-T cell therapy. The medication is given as an infusion into your vein every 3 weeks for up to 8 cycles. Researchers want to see if this treatment can help people whose cancer no longer responds to other available options.
CAR-T cell therapy is an advanced cancer treatment, but it doesn't work for everyone—some people's cancers come back or never respond in the first place. There is an urgent need for new treatment options for these patients, and this trial is exploring whether this medication could be a viable next step.
You likely qualify if…
You likely don't qualify if…
You will receive intravenous infusions of the medication every 3 weeks for up to 8 cycles (about 6 months of treatment). Each infusion takes about 30 minutes, and you'll be monitored closely for side effects during and after each visit. After your treatment ends, you'll be followed for 24 months with regular check-ins to see how well the treatment is working and to track any side effects. Doctors will use imaging scans to measure how your lymphoma responds to the medication.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
Italy